K930309 is an FDA 510(k) clearance for the ABBOTT ENCOUNTER(TM)Q. Classified as Counter, Differential Cell (product code GKZ), Class II - Special Controls.
Submitted by Abbott Laboratories (Abbott Park, US). The FDA issued a Cleared decision on July 14, 1993 after a review of 174 days - an extended review cycle.
This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.5220 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Hematology review framework, consistent with the majority of Class II 510(k) submissions.
View all Abbott Laboratories devices